Reuters Stock Buzz Powered by SocialPicks Logo_divider Logo_thomsonreuters Bg_dots_d1
   Sign Up   |   Log In   |   What is Reuters Stock Buzz?   |   FAQ powered by Logo_powered_by_socialpicks

 Pozen Inc.  (POZN)     Rate POZN  -  Discuss POZN  -  Add to Watch List         Graphic_subscribe

       Sector: Healthcare  >  Industry: Biotechnology & Drugs
SocialPicks Sentiment:

** v.s. other stocks 		This Quarter's Sentiment:
All:
100.0%
Top:
100.0%
Rate POZN:



POZN: Bull or Bear?

Astukphoto
-7.87%
 risk: low
The FDA's approval of Treximet should lead to profitability in the second quarter.  04/17/08
Pozen and partner GlaxoSmithKline announced late this evening that the U.S. Food and Drug Administration (FDA) has approved Treximet for the acute treatment of migraine attacks with or without aura in adults. The news was as expected and results in a $20 million milestone from Glaxo ($10 million for approval and $10 million for the launch) to be recorded by Pozen in the second ...




People Bullish on POZN

charles.waserstein
Analyst
74%
26 days ago

bluedog
Tracked Blogger
61%
4 mos ago

Zacks.com
Tracked Blogger
43%
4 mos ago

Astukphoto
Armin Stuk
Sr. Associate
37%
4 mos ago

Tommy C
Analyst
 3 %
about 1 year ago


People Bearish on POZN

 


Discussion Wall + Add  

Be the first to start a discussion and earn 2 points.



More Resources

Graphic_arrow1 About Pozen Inc. - Answers.com

Graphic_arrow1 Historical Prices - Yahoo

Graphic_arrow1 Message Boards - BoardCentral.com

Graphic_arrow1 More Info:     Yahoo   |   Google   |   Reuters